Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burden measured by amyloid-positron emission tomography (PET). We retrospectively identified subjects with mild cognitive impairment due to AD and HCs who underwent 3-T MRI, including a compressed-sensing MP2RAGE sequence, generating three-dimensional T1-weighted images and qT1 maps. Amyloid-PET was available for 16 patients. Hippocampal qT1 and volume were compared between groups, adjusting for age and sex; analyses were repeated after stratifying patients by Mini-Mental State Examination (MMSE). Voxel-wise group comparison was performed using SPM 12. The qT1-standardized uptake value ratio (SUVr) association was assessed with a linear mixed-effects model applied to voxel-level data, accounting for partial volume effects. Thirty-three AD subjects, aged 69.3 ± 8.2 years (mean ± standard deviation), 18 females, and 22 HCs aged 70.5 ± 13.3 years, 15 females, were evaluated. Regional hippocampal qT1 was higher in AD (1,398 ± 53.0 ms versus 1,349 ± 53.4 ms; p = 0.002), without difference across cognitive subgroups stratified by MMSE. AD subjects exhibited increased qT1 in mesial temporal gray matter and temporo-parieto-occipital cortices (1,448 ± 55.7 ms versus 1,344 ± 51.6 ms; p < 0.001). Voxel-level modelling revealed a positive association between qT1 and amyloid-PET SUVr (p < 0.001; d = 0.223). qT1 mapping can be sensitive to changes related to brain amyloidosis, supporting its role as a promising, noninvasive imaging biomarker in AD. Question Can qT1 mapping detect AD-related microstructural changes in the cortico-limbic gray matter? Findings Participants with AD showed increased cortico-limbic qT1 values. A subtle yet consistent positive association was observed between cortical qT1 values and amyloid-PET SUVr. Relevance statement qT1 mapping captures microstructural tissue alterations related to amyloid pathology in Alzheimer’s disease, supporting its role as a potential non-invasive imaging biomarker in this condition.
It is suggested that MRI-derived measures of cortical thickness, tissue volumes, BPV, and BPF provide useful structural biomarkers of AD and emphasize the importance of considering voxel geometry and segmentation methodology when evaluating neuroimaging biomarkers.
PD-MCI was characterized by distributed hippocampal diffusivity alterations despite the absence of detectable volumetric differences, and subfield-specific diffusion measures may provide complementary information on cognition-related hippocampal involvement beyond conventional volumetry.
Yu-Mei Chen, Lu Peng, Qing Hu et al.· Frontiers in Aging Neuroscie...· 0 citations
Objectives: Developing sensitive imaging biomarkers is critical for capturing early brain alterations in Alzheimer’s disease. This exploratory study aimed to evaluate how multiparametric magnetic resonance imaging (MRI) measures, including chemical exchange saturation transfer (CEST) imaging, can detect early cognitive...
Zong-Pai Zhang, Jing-Pu Wu, Isabel M. Rios Pulgar et al.· Neurology International· 0 citations
Evidence is provided that multiregion T1‐MRI patterns can inform on tau‐PET burden in AD and may support approximate tau staging when tau‐PET is unavailable, especially in subjects with more advanced tau burden.
Martina Pulze, S. Garbarino, L. Lorenzini et al.· Alzheimer's & Dementia· 0 citations
Overall, the association between cerebral metabolic dysfunction and cognitive impairment appeared to be predominantly direct, with limited evidence supporting a mediating role of regional GMV.
Shi-Qi Zhao, Jian-Wen Chen, Pei-Xue Li et al.· Frontiers in Neurology· 0 citations
Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.
Arthur C. Macedo, Lydia Trudel, S. A. Hosseini et al.· EBioMedicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.